A few hours ago, a very good report emerged that a vaccine for HIV has finally been discovered and approved by the American food and drug administration. This vaccine will be administered to HIV-positive people twice a year relieving these people of the burden of taking ARVs daily.
Photo courtesy, image used for evidence purposes only.
According to the report, this vaccine will be given to people living with HIV for five million Kenya shillings per year and an additional 4.5 million Kenya shillings. This vaccine will thus be available only to those who will be able to afford it.
Photo courtesy, image used for illustration purposes only.
This vaccine has served as proof that the cure to HIV will soon be discovered by the American food and drug administration for more research on HIV is still being carried out. Please share your thoughts on this matter in the comments section below. Please do like, comment and share.
Content created and supplied by: Sunflower (via Opera News )
Opera News is a free to use platform and the views and opinions expressed herein are solely those of the author and do not represent, reflect or express the views of Opera News. Any/all written content and images displayed are provided by the blogger/author, appear herein as submitted by the blogger/author and are unedited by Opera News. Opera News does not consent to nor does it condone the posting of any content that violates the rights (including the copyrights) of any third party, nor content that may malign, inter alia, any religion, ethnic group, organization, gender, company, or individual. Opera News furthermore does not condone the use of our platform for the purposes encouraging/endorsing hate speech, violation of human rights and/or utterances of a defamatory nature. If the content contained herein violates any of your rights, including those of copyright, and/or violates any the above mentioned factors, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com and/or report the article using the available reporting functionality built into our Platform See More